We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Although the FDA is rebidding its contract for a consultant to help rewrite the Part 11 regulation and related guidance documents, publication of a revision is not expected in the near future.